Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Acquisition work for Diageo PLC
Assisted Diageo PLC with various aspects of an acquisition of portions of Seagram Spirits division, including transfer of domain names, performance more
Jan K. Voda v. Medtronic Inc., et al.
Served as lead counsel on behalf of Jan Voda, M.D., a cardiologist, in a patent infringement suit related to angioplasty catheters against Medtronic, more
Boardman Petroleum, Inc. v. Federated Mut. Ins. Co.
The firm served as lead counsel to Boardman Petroleum in two significant actions resulting in reported decisions. The first action was brought more
Trademark counsel for the American Cancer Society
Represents the American Cancer Society in trademark matters and in opposition and cancellation proceedings before the Trademark Trial and Appeal more